Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 18, Issue 6, Pages 805-819Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780902905848
Keywords
autoantibodies; idiopathic thrombocytopenia purpura; megakaryocytes; platelets; thrombopoietin
Categories
Ask authors/readers for more resources
Background: The efficacy of thrombopoietin (TPO) mimetics in patients with idiopathic thrombocytopenic purpura (ITP) reaffirms that impaired platelet production is an important mechanism. New strategies to reduce platelet destruction, like rituximab, are also effective. Objectives: To describe the efficacy and safety of rituximab and the TPO mimetics, romiplostim and eltrombopag, and how they relate to ITP pathogenesis. Methods: Narrative review summarizing full publications and meeting abstracts. Results/conclusions: A 4-week course of rituximab is associated with a platelet count response in 60% of patients with ITP, and durable responses have been observed. Subtle increases in infection have been reported. Romiplostim and eltrombopag are each associated with a 60 - 85% response while on treatment. Transient bone marrow reticulin with romiplostim and elevated liver enzymes with eltrombopag are rare side effects. The application of these agents in non-splenectomized patients requires further study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available